一名82岁女性同步复发性肺癌中的表皮生长因子受体突变。病例报告。 - Suppr | 超能文献

Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.

作者信息

Kristiansen Charlotte, Olsen Karen Ege, Hansen Niels Christian, Hansen Karin Holmskov, Hansen Olfred

出版信息

Acta Oncol. 2012 Sep;51(7):948-9. doi: 10.3109/0284186X.2011.652739. Epub 2012 Apr 4.

DOI:10.3109/0284186X.2011.652739

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.一名82岁女性同步复发性肺癌中的表皮生长因子受体突变。病例报告。

Acta Oncol. 2012 Sep;51(7):948-9. doi: 10.3109/0284186X.2011.652739. Epub 2012 Apr 4.

2

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.一名携带EGFR突变的转移性非小细胞肺癌患者使用厄洛替尼进行再治疗：病例报告

Tumori. 2014 May-Jun;100(3):e70-3. doi: 10.1700/1578.17234.

3

Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.吉非替尼治疗肺腺癌有效后行肺切除术。

Asian Cardiovasc Thorac Ann. 2013 Aug;21(4):482-4. doi: 10.1177/0218492312462834. Epub 2013 Jul 9.

4

Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?厄洛替尼用于并存典型支气管类癌和晚期肺腺癌：表皮生长因子受体突变状态重要吗？

Anticancer Drugs. 2018 Mar;29(3):281-285. doi: 10.1097/CAD.0000000000000587.

5

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.基于体积的肿瘤生长动力学作为接受表皮生长因子受体酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型肺腺癌患者的预后生物标志物：一项病例对照研究。

Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.

6

Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.厄洛替尼用于治疗具有敏感表皮生长因子受体（EGFR）突变的肺腺癌所致有症状脑转移瘤。

J Thorac Oncol. 2012 Jun;7(6):1059-60. doi: 10.1097/JTO.0b013e31824cc34a.

7

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ()-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.波齐替尼在对表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂产生耐药的EGFR突变型肺腺癌患者中的II期研究。

Cancer Res Treat. 2017 Jan;49(1):10-19. doi: 10.4143/crt.2016.058. Epub 2016 May 3.

8

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

9

EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.表皮生长因子受体（EGFR）第18外显子E709_T710缺失并插入D突变的IV期肺腺癌，对阿法替尼有反应。

Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.

10

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.表皮生长因子受体（EGFR）突变L747P导致一名中国肺腺癌患者对吉非替尼产生耐药，并加速了肝转移。

Int J Clin Exp Pathol. 2015 Jul 1;8(7):8603-6. eCollection 2015.